KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

GoodRx Holdings (GDRX) Cash from Financing Activities (2019 - 2025)

GoodRx Holdings' Cash from Financing Activities history spans 7 years, with the latest figure at -$12.8 million for Q4 2025.

  • For Q4 2025, Cash from Financing Activities fell 263.37% year-over-year to -$12.8 million; the TTM value through Dec 2025 reached -$234.5 million, up 30.53%, while the annual FY2025 figure was -$234.5 million, 30.53% up from the prior year.
  • Cash from Financing Activities for Q4 2025 was -$12.8 million at GoodRx Holdings, up from -$65.8 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at -$864000.0 in Q2 2024 and bottomed at -$172.1 million in Q3 2024.
  • The 5-year median for Cash from Financing Activities is -$14.0 million (2021), against an average of -$44.5 million.
  • The largest annual shift saw Cash from Financing Activities surged 97.19% in 2024 before it crashed 5794.44% in 2025.
  • A 5-year view of Cash from Financing Activities shows it stood at -$11.5 million in 2021, then surged by 58.26% to -$4.8 million in 2022, then crashed by 2524.43% to -$125.6 million in 2023, then soared by 97.19% to -$3.5 million in 2024, then tumbled by 263.37% to -$12.8 million in 2025.
  • Per Business Quant, the three most recent readings for GDRX's Cash from Financing Activities are -$12.8 million (Q4 2025), -$65.8 million (Q3 2025), and -$50.9 million (Q2 2025).